Showing papers for search query "FDA"+"Best+practice"+OR+"General+guidelines"

     Search term "FDA"+"Best+practice"+OR+"General+guidelines"
     Title Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions
     Author ['P Zhao', 'M Rowland', 'SM Huang']
     Venue Clinical pharmacology & …
     Year 2012
     Abstract Opinion. Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions. P Zhao Corresponding Author. E-mail address: ping.zhao@fda.hhs.gov
     Url https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1038/clpt.2012.68


     Search term "FDA"+"Best+practice"+OR+"General+guidelines"
     Title A best practice approach to learning compliance management in regulated industries
     Author ['J Ambrose']
     Venue Industrial and commercial training
     Year 2008
     Abstract For many firms, this still means largely manual processes. However, organisations are now progressively choosing to follow the “best practice” model that the FDA regulations offers because of the efficiency gains of using a compliant LMS
     Url https://www.emerald.com/insight/content/doi/10.1108/00197850810868630/full/html


     Search term "FDA"+"Best+practice"+OR+"General+guidelines"
     Title Unresolved issues in dialysis: dialyzer best practice: single use or reuse?
     Author ['E Lacson Jr', 'JM Lazarus']
     Venue Seminars in dialysis
     Year 2006
     Abstract The quality controls for reprocessing of dialyzers are not equal to the rigor of the manufacturing process under the purview of the US Food and Drug Administration (FDA). Therefore, if one were to determine “best practice,” single use is preferable to reuse of dialyzers based on
     Url https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1525-139X.2006.00137.x


     Search term "FDA"+"Best+practice"+OR+"General+guidelines"
     Title Quality management benchmarking: FDA compliance in pharmaceutical industry
     Author ['R Jochem', 'K Landgraf']
     Venue International journal of health care quality …
     Year 2010
     Abstract Best practice solutions were identified in two companies using a benchmarking method and five‐stage model  Roland Jochem and Katja Landgraf (2010) "Quality management benchmarking: FDA compliance in pharmaceutical industry", International Journal of Health Care
     Url https://www.emerald.com/insight/content/doi/10.1108/09526861011081813/full/html


     Search term "FDA"+"Best+practice"+OR+"General+guidelines"
     Title General guidelines for clinical bacteriology
     Author ['LD Thrupp', 'R Cleeland', 'RN Jones']
     Venue Clinical infectious …
     Year 1992
     Abstract These guidelines deal with the conduct of phase I through phase 4 clinical trials and are subsets ofthe General Guidelines for the Clinical  components ofclinical trials; (3) con- tinually updating the guidelines set forth by the US Food and Drug Administration (FDA); (4) reviewing
     Url https://academic.oup.com/cid/article-abstract/15/Supplement_1/S339/273091


     Search term "FDA"+"Best+practice"+OR+"General+guidelines"
     Title WHO best-practice statement on the off-label use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis
     Author ['World Health Organization']
     Venue NA
     Year 2017
     Abstract 1 WHO best-practice statement on the off-label use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis  Bedaquiline • In December 2012, the United States Food and Drug Administration (US-FDA) approved bedaquiline, a new antibiotic, as part of
     Url https://apps.who.int/iris/bitstream/handle/10665/258941/WHO-HTM-TB-2017.20-eng.pdf


     Search term "FDA"+"Best+practice"+OR+"General+guidelines"
     Title Proof of concept: a PhRMA position paper with recommendations for best practice
     Author ['ME Cartwright', 'S Cohen', 'JC Fleishaker']
     Venue Clinical …
     Year 2010
     Abstract Proof of Concept: A PhRMA Position Paper With Recommendations for Best Practice. ME Cartwright  Search for more papers by this author. S Madani FDA Liaison and Policy Office, Drug Regulatory Affairs, Novartis Inc., Rockville, Maryland, USA
     Url https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1038/clpt.2009.286


     Search term "FDA"+"Best+practice"+OR+"General+guidelines"
     Title A best practice position statement on pregnancy in chronic kidney disease: the Italian Study Group on Kidney and Pregnancy
     Author ['G Cabiddu', 'S Castellino', 'G Gernone', 'D Santoro']
     Venue Journal of …
     Year 2016
     Abstract Main features. FDA  Azathioprine. This is the most widely used immunosuppressive drug. It is teratogenic in animal models, but not in humans, possibly because the foetal liver is not able to activate the drug. K-DIGO and European Best Practice Guidelines suggest switching from
     Url https://link.springer.com/article/10.1007/s40620-016-0285-6


     Search term "FDA"+"Best+practice"+OR+"General+guidelines"
     Title STP position paper: best practice guideline for the routine pathology evaluation of the immune system
     Author ['STP Immunotoxicology Working Group']
     Venue Toxicologic …
     Year 2005
     Abstract Download Citation. Download article citation data for: STP Position Paper: Best Practice Guideline for the Routine Pathology Evaluation of the Immune System. P. Haley, R. Perry, D. Ennulat, S. Frame, C. Johnson, JM Lapointe, A. Nyska, PW Snyder, D. Walker, and G. Walter
     Url https://journals.sagepub.com/doi/full/10.1080/01926230590934304


     Search term "FDA"+"Best+practice"+OR+"General+guidelines"
     Title Best‐practice algorithms for the use of a bilayered living cell therapy (Apligraf®) in the treatment of lower‐extremity ulcers
     Author ['J Cavorsi', 'F Vicari', 'DJ Wirthlin', 'W Ennis']
     Venue Wound repair and …
     Year 2006
     Abstract we describe the development of guidelines surrounding best‐practice use of one specific tissue engineered product, Apligraf ® , in the treatment of two types of lower extremity ulcers: VLU and DFU.13-19 Apligraf ® , a bilayered living cell therapy, is currently FDA approved for
     Url https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1743-6109.2006.00098.x

